Yoga During Chemotherapy Study

Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT02442635
Collaborator
National Center for Complementary and Integrative Health (NCCIH) (NIH)
73
1
3
53
1.4

Study Details

Study Description

Brief Summary

This proposal aims to expand non-pharmacologic options for the control of symptoms during chemotherapy using yoga practices. It is particularly focused on sleep disturbance with a secondary focus on fatigue.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Yoga
N/A

Detailed Description

Sleep disturbance is among the most common symptoms experienced by cancer patients, occurs in up to 80% of patients during chemotherapy, and results in serious impairments in quality of life. Although pharmacologic therapies improve sleep disturbance, they have numerous side effects, problems with tolerance and dependence, and are not well studied in oncology patients. While non-pharmacologic therapies may decrease sleep disturbance, the current level of evidence on their efficacy is insufficient. Fatigue occurs in up to 95% of those receiving chemotherapy, and results in major impairments in functioning and quality of life. Despite its significance, few effective treatments currently exist for fatigue. Prior studies suggest that yoga may be helpful for sleep disturbance and fatigue, but these studies have limitations. An important challenge in yoga research is that it is typically a multi-modality practice that can include physical postures, breathing practices, and/or meditation components. Prior studies have not adequately addressed the effects of individual components. Therefore, key questions remain unanswered about the most effective elements of yoga; how to best combine them for particular problems such as chemotherapy symptoms; and optimal dosing. The current study will address these gaps in the literature and perform key developmental steps to prepare for a large randomized, controlled trial (RCT). It builds on preliminary work in which yoga breathing practices during chemotherapy were found to improve sleep disturbance, showed trends toward improvements in fatigue, and were feasible to implement in patients undergoing chemotherapy. Using a mixed-methods approach to evaluate each intervention component, the investigators will pursue three closely interlinked steps in cancer patients receiving chemotherapy. In Aim 1 (n=10), the investigators will manualize an individualized approach to the yoga breathing intervention and iteratively refine it to insure feasibility and acceptability. In Aim 2 (n=20), the investigators will manualize a yoga posture intervention, evaluating both restorative/static poses and flowing poses, and perform iterative refinement to test feasibility and acceptability. In Aim 3 (n=70), the investigators will assess the final multi-modality yoga intervention to select final intervention elements and delivery methods for testing in a planned future RCT. This proposal will help to improve the treatment of debilitating cancer associated symptoms and advance approaches to developing therapeutic yoga intervention trials.

Study Design

Study Type:
Interventional
Actual Enrollment :
73 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Developing a Yoga Intervention During Cancer Chemotherapy
Study Start Date :
May 1, 2015
Actual Primary Completion Date :
Oct 1, 2019
Actual Study Completion Date :
Oct 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Condition 1

Yoga Breathing

Behavioral: Yoga
Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.

Experimental: Condition 2

Static Yoga

Behavioral: Yoga
Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.

Experimental: Condition 3

Flowing Yoga

Behavioral: Yoga
Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.

Outcome Measures

Primary Outcome Measures

  1. Sleep Disturbance as measured by the General Sleep Disturbance Scale [6 weeks]

Secondary Outcome Measures

  1. Fatigue as measured by the Lee Fatigue Scale [6 weeks]

Other Outcome Measures

  1. Quality of Life as measured by the Multidimensional Quality of Life Scale--Cancer [6 weeks]

  2. Depressive Symptoms as measured by the CES-D [6 weeks]

  3. Anxiety as measured by the Spielberger State Anxiety Inventory [6 weeks]

  4. Pain as measured by the modified Brief Pain Inventory [6 weeks]

  5. Hot Flashes as measured by the Hot Flash Related Daily Interference Scale [6 weeks]

  6. Mindfulness as measured by the Five Facet Mindfulness Questionnaire [6 weeks]

  7. Body Awareness as measured by the Multidimensional Assessment of Interoceptive Awareness [6 weeks]

  8. Coping and Self Efficacy as measured by the Coping and Self Efficacy Scale [6 weeks]

  9. Social Support as measured by single items on social support [6 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 and older

  • Have a Karnofsky Performance Status Score of 60 or above

  • Diagnosed with any cancer except acute leukemia

  • Self-reported poor quality of sleep

  • Receiving Chemotherapy

  • Able to read, write, and understand English

  • Ability to give informed consent

Exclusion Criteria:
  • Diagnosed with brain metastasis

  • Diagnosed with severe Chronic Obstructive Pulmonary Disease (COPD) or emphysema

  • Have New York Heart Association class II or greater congestive heart failure

  • Requiring chronic home oxygen therapy

  • Diagnosed with a sleep disorder (e.g., sleep apnea or narcolepsy)

  • Have received more than 3 prior chemotherapy regimens

  • Receiving radiation therapy

  • Has a less than 6 month life expectancy

  • Regular yoga practice within the last 2 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 UCSF San Francisco California United States 94110

Sponsors and Collaborators

  • University of California, San Francisco
  • National Center for Complementary and Integrative Health (NCCIH)

Investigators

  • Principal Investigator: Anand Dhruva, MD, University of California, San Francisco

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT02442635
Other Study ID Numbers:
  • 15-15691
  • R34AT007935
  • 15991
First Posted:
May 13, 2015
Last Update Posted:
Nov 14, 2019
Last Verified:
Nov 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 14, 2019